Unknown primary tumors metastatic to liver

被引:66
作者
Ayoub, JP
Hess, KR
Abbruzzese, MC
Lenzi, R
Raber, MN
Abbruzzese, JL
机构
[1] Univ Texas, MD Anderson Cancer Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Cancer Ctr, Dept Digest Dis, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Cancer Ctr, Dept Clin Invest, Houston, TX 77030 USA
[4] Univ Texas, MD Anderson Cancer Ctr, Dept Biomath, Houston, TX 77030 USA
[5] Univ Texas, MD Anderson Cancer Ctr, Div Med, Houston, TX 77030 USA
关键词
D O I
10.1200/JCO.1998.16.6.2105
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The objectives of this study were to identify prognostic factors for unknown primary tumor (UPT) patients with hepatic metastases, determine the common primary tumors identified, assess the yield of specific diagnostic studies, and evaluate the impact of therapy on survival. Patients and Methods: The 1,522 patients analyzed were referred from January 1, 1987 through June 30, 1995. Clinical data from these patients were entered into a computerized database for storage, retrieval, and analysis. Survival was measured from the time af diagnosis; survival distribution was estimated by the product limit method. Multivariate survival analyses were performed by proportional hazards regression. Results: Five hundred UPT patients had liver metastases. Primary tumors, usually lung, colorectal, or pancreatic neoplasms, were identified in 135 patients (27%), The remaining 365 unknown primary carcinoma (UPC) patients with liver involvement had a higher death rate than those without liver involvement (hazards ratio, 1.63; P < .0001). Neuroendocrine carcinoma patients had a lower death rate than patients without this histology (hazards ratio, 0.29; P < .0001). Two hundred sixteen of 365 patients with UPC and liver metastases received chemotherapy. Chemotherapy-treated patients had a lower death rate than those who were not treated with chemotherapy (hazards ratio, 0.52; P < .0001). The effect of chemotherapy was most pronounced in patients with adenocarcinoma. Conclusion: Hepatic metastases in UPC patients portend a generally poor prognosis. However, subsets of patients with more favorable outcomes can be identified by available clinical and pathologic data. Chemotherapy may be beneficial for the large subset of UPC patients with adenocarcinoma that involves the liver.
引用
收藏
页码:2105 / 2112
页数:8
相关论文
共 26 条
[11]   METASTATIC ADENOCARCINOMAS OF UNKNOWN PRIMARY SITE - PROGNOSTIC VARIABLES AND TREATMENT RESULTS [J].
KAMBHU, SA ;
KELSEN, DP ;
FIORE, J ;
NIEDZWIECKI, D ;
CHAPMAN, D ;
VINCIGUERRA, V ;
ROSENBLUTH, R .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1990, 13 (01) :55-60
[12]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[13]   COMPUTED-TOMOGRAPHY IN SEARCH OF CANCER OF UNKNOWN ORIGIN [J].
KARSELL, PR ;
SHEEDY, PF ;
OCONNELL, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1982, 248 (03) :340-343
[14]  
LECESNE A, 1991, PRESSE MED, V20, P1369
[15]   Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: Favorable subsets of patients with unknown-primary carcinoma? [J].
Lenzi, R ;
Hess, KR ;
Abbruzzese, MC ;
Raber, MN ;
Ordonez, NG ;
Abbruzzese, JL .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :2056-2066
[16]  
MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163
[17]   STREPTOZOCIN DOXORUBICIN, STREPTOZOCIN FLUOROURACIL, OR CHLOROZOTOCIN IN THE TREATMENT OF ADVANCED ISLET-CELL CARCINOMA [J].
MOERTEL, CG ;
LEFKOPOULO, M ;
LIPSITZ, S ;
HAHN, RG ;
KLAASSEN, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (08) :519-523
[18]  
MOUSSEAU M, 1991, B CANCER, V78, P725
[19]   PRESENTATION OF UNKNOWN PRIMARY-CANCER WITH METASTATIC LIVER-DISEASE - MANAGEMENT AND NATURAL-HISTORY [J].
NESBIT, RA ;
TATTERSALL, MHN ;
FOX, RM ;
WOODS, RL .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1981, 11 (01) :16-19
[20]  
NYSTROM JS, 1977, SEMIN ONCOL, V4, P53